Sinopharm CNBG COVID-19 vaccine

For other uses, see Sinopharm COVID-19 vaccine.

Sinopharm CNBG COVID-19 vaccine

Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of administration	Intramuscular
Legal status
Legal status	Full list of Sinopharm NVSI authorizations
Identifiers
CAS Number	2503126-65-4[1]

Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm.^[2][3]

They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD).^[4] It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants.^[5]

References

1. "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
2. "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. Retrieved 27 December 2021.
3. "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
4. 國藥集團：二代重組蛋白新冠疫苗保護效果良好
5. Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. (June 2022). "Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial". Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812.